Sichuan Kelun Pharmaceutical (SHE:002422) won bids for 14 of its products under China's drug procurement system, according to a Monday filing with the Shenzhen bourse.
The drugs treat cardiovascular and blood pressure-related problems, prostate cancer, depression and anxiety, fungal infections, and rheumatoid arthritis, among others, the filing said.
The company also won bids for its nutritional supplements and oral contraceptives for women.
Shares fell 3% during the midday break on Monday.